The Food and Drug Administration (FDA) has launched CURE ID, an internet-based repository that allows clinicians to report their experiences using existing FDA-approved drugs for difficult-to-treat infections.
CURE ID works by capturing clinical outcomes when drugs are used for new indications, populations, doses or combinations; cases that include novel uses of existing drugs can be uploaded via a form available through a website, smartphone, or other mobile device. The app includes data related to 325 different infectious diseases and syndromes, nearly 1500 initial case reports, and over 18,000 clinical trials.
Using the search function, healthcare professionals are able to browse through a collection of cases that report on both successful and unsuccessful treatments. In addition, a treatment discussion forum allows clinicians to engage with peers globally to identify potentially successful treatments for difficult infectious disease cases.
“The CURE ID application focuses on drugs for infectious diseases lacking adequate treatments, including neglected tropical diseases, emerging infectious threats and infections caused by antimicrobial-resistant organisms,” said Amy Abernethy, MD, PhD, FDA Principal Deputy Commissioner. “When healthcare professionals directly input their clinical cases into the app, CURE ID allows these real-world experiences to be organized and analyzed much faster, making it easier to spot promising new uses for existing drugs.”
For more information visit https://cure.ncats.io/ or download CURE ID from the App or Google Play Store.
This article originally appeared on MPR